Drug Coverage

Abiraterone is used together with prednisone to treat patients with metastatic prostate cancer.

The Inflation Reduction Act also allows Medicare to negotiate prices on some drugs and caps out-of-pocket costs for Medicare beneficiaries.

The new code, effective Oct. 1, 2022, allows APDS to be recognized as an distinct immunological disease.

Investigators found that socioeconomic and financial barriers can affect patients’ access to oral cancer medications. They suggest that addressing these barriers could improve adherence.

Prime has removed six drugs from its formularies because generics are now available. One has been removed because it has been discontinued.

Optum has teamed up with Sanofi to provide savings cards for six insulins through the Optum Store.

The prescription drug launches include a therapy to treat adults with multiple myeloma and a treatment for overactive bladder. Dr. Reddy’s has also acquired several therapies from Eton Pharmaceuticals, including hypotension treatments.

Orsini Specialty Pharmacy has been chosen as the exclusive pharmacy provider of Ztalmy.

The bipartisan bill introduced in the Senate in May would require PBMs to report to the FTC how much money they make through spread pricing and pharmacy fees.

Next year, seven biosimilars of Humira are expected to launch, but leaders from the Biosimilars Forum are concerned not all will make it onto formularies.

Many products added to the Express Scripts preferred drug list include prior authorization and other utilization management tools.

David Lassen, Pharm.D., chief clinical officer at Prime, discusses a pilot program that used a predictive model to identify patients at high risk of overusing opioids.

The organization claims that direct and indirect remuneration fees and other clawback programs amount to a breach of contract.

Navitus senior vice president and chief pharmacy officer Brent Eberle talks about how partnering with CivicaScript fits into its cost-plus model.

Vivjoa, approved by the FDA in April 2022, is an oral therapy and the first for chronic yeast infections.

Some insulins, as well as some drugs used in emergency care, will now be offered at $0 copay for eligible patients.

Investigators suggest that policies that improve price transparency and increase competition for generic drugs could prevent patients and Medicare from overpaying on generic drugs.

Drugs approved with an FDA breakthrough designation can provide value that offsets their higher costs, finds study conducted by Tufts Center for the Evaluation of Value and Risk in Health.

In 2023, a wave of biosimilar launches is expected, including seven biosimilars of Humira.

In the future, payers plan to leverage reinsurance and value- or outcomes-based contracting to provide access to high-cost therapies.

Blue Cross Blue Shield of North Carolina found that uptake of Trikafta was rapid after approval and total cost of care increased 52% despite reductions in hospitalizations and nonpharmacy costs.

Under a new add-on program, plan members will have access to an expanded list of FDA-approved specialty generic medications with no copays.

The removal of prior authorizations for buprenorphine for use in opioid use disorder was associated with a statistically significant increase in the number of prescriptions filled among Medicaid populations in Illinois but not in California, which had already been seeing an increase in use of such therapies.

Effective July 1, 2022, CVS Caremark has removed 16 drugs and added 14 to its Standard Control Formulary.

Zelnorm is used to treat adult women less than 65 years of age with irritable bowel syndrome with constipation.

Sanofi has lowered the out-of-pocket cost for those without insurance of its insulins to $35 for a 30-day supply through the company’s savings program.

Diacomit was approved in 2018 for seizures associated with Dravet syndrome, a rare pediatric disorder.

Benefits leaders surveyed in PSG’s Trends in Drug Benefit Design Report say the importance of the member experience has increased since the start of the pandemic.

Xipere became commercially available in March 2022. It is the first therapy for patients with macular edema that provides a targeted delivery to the retina.

A study in the journal Blood has found that the cost-effectiveness of the Polivy treatment regimen used to treat patients with diffuse large B-cell lymphoma would decrease if the five-year progression-free survival decreased.